Structure via PubChem · Public domain (PubChem)
fedratinib
Sign in to saveAlso known as SAR302503, TG-101348, TG101348
Fedratinib, sold under the brand name Inrebic, is an anti-cancer medication used to treat myeloproliferative diseases including myelofibrosis. It is used in the form of fedratinib hydrochloride capsules that are taken by mouth. It is a semi-selective inhibitor of Janus kinase 2 (JAK-2). It was approved by the FDA on 16 August 2019.
Chemical data
- Formula
- C27H36N6O3S
- Molecular weight
- 524.7 g/mol
- IUPAC name
- N-tert-butyl-3-[[5-methyl-2-[4-(2-pyrrolidin-1-ylethoxy)anilino]pyrimidin-4-yl]amino]benzenesulfonamide
- SMILES
- CC1=CN=C(N=C1NC2=CC(=CC=C2)S(=O)(=O)NC(C)(C)C)NC3=CC=C(C=C3)OCCN4CCCC4
- InChIKey
- JOOXLOJCABQBSG-UHFFFAOYSA-N
- XLogP
- 4.8
- Polar surface area
- 117 Ų
- H-bond donors
- 3
- H-bond acceptors
- 9
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2019
- Admin. routes
- oral
- Indications
- neoplasm, primary myelofibrosis, liver disease, kidney disease
via ChEMBL · EBI
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 524.257
- Has use
- medication
Show 5 more facts
- Commons category
- Fedratinib
- medical condition treated
- myelofibrosis
- canonical SMILES
- CC1=CN=C(N=C1NC2=CC(=CC=C2)S(=O)(=O)NC(C)(C)C)NC3=CC=C(C=C3)OCCN4CCCC4
- chemical formula
- C₂₇H₃₆N₆O₃S
- subject has role
- protein kinase inhibitors
Sources (2)
via Wikidata · CC0
~3 min read
Encyclopedic overview
6 sectionsContents
- Medical uses
- Pharmacology
- Mechanism of action
- History
- References
- External links
Fedratinib, sold under the brand name Inrebic, is an anti-cancer medication used to treat myeloproliferative diseases including myelofibrosis. It is used in the form of fedratinib hydrochloride capsules that are taken by mouth. It is a semi-selective inhibitor of Janus kinase 2 (JAK-2). It was approved by the FDA on 16 August 2019.
Myelofibrosis is a myeloid cancer associated with anemia, splenomegaly, and constitutional symptoms. Patients with myelofibrosis frequently harbor mutations which activate the JAK-STAT signaling pathway and which are sensitive to fedratinib. Phase I trial results focused on safety and efficacy of fedratinib in patients with high- or intermediate-risk primary or post–polycythemia vera/essential thrombocythemia myelofibrosis have been published in 2011.
Excerpted from Wikipedia’s “fedratinib” article, available under the CC BY-SA 4.0 licence.